source
- Novartis halts ALS drug VHB937 after phase 2 trial fails to meet endpointsNovartis announced it is stopping development of its ALS candidate VHB937 after the phase 2 Astrals trial did not meet its primary or secondary endpoints. The study enrolled 251 patients with earl…
- FDA holds psychedelic forum as Definium reports third successful Phase 3 trial of oral LSD for anxietyThe FDA convened a public forum on Monday to discuss the near‑term outlook for psychedelic drug development, highlighting interest from companies such as Compass Pathways and Definium Therapeutics.…